NO303221B1 - Hydroksaminsyrederivater - Google Patents
HydroksaminsyrederivaterInfo
- Publication number
- NO303221B1 NO303221B1 NO950226A NO950226A NO303221B1 NO 303221 B1 NO303221 B1 NO 303221B1 NO 950226 A NO950226 A NO 950226A NO 950226 A NO950226 A NO 950226A NO 303221 B1 NO303221 B1 NO 303221B1
- Authority
- NO
- Norway
- Prior art keywords
- acid derivatives
- hydroxamic acid
- substituted phenyl
- hydrogen
- phenyl
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929215665A GB9215665D0 (en) | 1992-07-23 | 1992-07-23 | Compounds |
| PCT/GB1993/001557 WO1994002447A1 (fr) | 1992-07-23 | 1993-07-23 | Derives d'acide hydroxamique en tant qu'inhibiteurs de metalloproteinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO950226D0 NO950226D0 (no) | 1995-01-20 |
| NO950226L NO950226L (no) | 1995-01-20 |
| NO303221B1 true NO303221B1 (no) | 1998-06-15 |
Family
ID=10719178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO950226A NO303221B1 (no) | 1992-07-23 | 1995-01-20 | Hydroksaminsyrederivater |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US5643964A (fr) |
| EP (3) | EP0651739B1 (fr) |
| JP (3) | JP2768554B2 (fr) |
| KR (1) | KR100205710B1 (fr) |
| AT (3) | ATE198331T1 (fr) |
| AU (2) | AU661410B2 (fr) |
| CA (1) | CA2140626C (fr) |
| CY (1) | CY1944A (fr) |
| CZ (1) | CZ285896B6 (fr) |
| DE (5) | DE9321495U1 (fr) |
| DK (2) | DK0754688T3 (fr) |
| ES (1) | ES2153927T3 (fr) |
| FI (1) | FI114549B (fr) |
| GB (4) | GB9215665D0 (fr) |
| GR (2) | GR3023522T3 (fr) |
| HK (1) | HK149396A (fr) |
| HU (2) | HU220625B1 (fr) |
| NO (1) | NO303221B1 (fr) |
| NZ (1) | NZ254862A (fr) |
| PL (1) | PL174279B1 (fr) |
| PT (1) | PT754688E (fr) |
| RU (1) | RU2126791C1 (fr) |
| SK (1) | SK281240B6 (fr) |
| UA (1) | UA29450C2 (fr) |
| WO (2) | WO1994002446A1 (fr) |
| ZA (2) | ZA935351B (fr) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9307956D0 (en) * | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
| ES2075797B1 (es) * | 1993-08-18 | 1996-05-16 | British Bio Technology | Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina. |
| ES2075798B1 (es) * | 1993-08-18 | 1996-03-01 | British Bio Technology | Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina. |
| JPH09503201A (ja) * | 1993-08-23 | 1997-03-31 | イミュネックス・コーポレーション | Tnf−アルファ分泌の阻害剤 |
| US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
| GB9401129D0 (en) * | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
| GB2299335B (en) * | 1994-01-21 | 1997-12-17 | British Biotech Pharm | Hydroxamic acid derivatives as metalloproteinase inhibitors |
| EP0905126B1 (fr) * | 1994-01-22 | 2002-12-04 | British Biotech Pharmaceuticals Limited | Inhibiteurs de métalloprotéinase |
| GB9404046D0 (en) * | 1994-03-03 | 1994-04-20 | Smithkline Beecham Corp | Novel compounds |
| GB9411088D0 (en) * | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
| GB9416897D0 (en) * | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
| GB9423914D0 (en) * | 1994-11-26 | 1995-01-11 | British Biotech Pharm | Polyether derivatives as metalloproteinase inhibitors |
| US5639746A (en) * | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
| AU5002196A (en) * | 1995-03-28 | 1996-10-16 | Novo Nordisk A/S | Immunosuppressive agents |
| US5691381A (en) * | 1995-04-18 | 1997-11-25 | The Dupont Merck Pharmaceutical Company | Hydroxamic and carbocyclic acids as metalloprotease inhibitors |
| GB9507799D0 (en) * | 1995-04-18 | 1995-05-31 | British Biotech Pharm | Metalloproteinase inhibitors |
| WO1996033968A1 (fr) * | 1995-04-25 | 1996-10-31 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Inhibiteur des metalloproteinases, tres soluble dans l'eau |
| AU692102B2 (en) * | 1995-05-10 | 1998-05-28 | Darwin Discovery Limited | Peptidyl compounds and their therapeutic use |
| US5917090A (en) * | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
| GB9513331D0 (en) * | 1995-06-30 | 1995-09-06 | British Biotech Pharm | Matrix metalloproteinase inhibitors |
| WO1997003966A1 (fr) * | 1995-07-19 | 1997-02-06 | British Biotech Pharmaceuticals Limited | Derives d'amide d'acide succinique a substitution n-(aminoacide) utilises comme inhibiteurs de la metalloproteinase |
| GB2318353B (en) * | 1995-07-20 | 1999-10-06 | British Biotech Pharm | Metalloproteinase inhibitors |
| GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
| US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
| GB9523637D0 (en) * | 1995-11-18 | 1996-01-17 | British Biotech Pharm | Synthesis of carboxylic acid derivatives |
| IL123431A (en) * | 1995-11-22 | 2001-05-20 | Darwin Discovery Ltd | Mercaptoalkyl peptidil compounds with imidazole transducer and their use as metallic protonase matrix (MMP) compounds and / or tumor cause factor (TNF) |
| ATE205184T1 (de) | 1995-11-23 | 2001-09-15 | British Biotech Pharm | Metalloproteinase inhibitoren |
| GB9609702D0 (en) | 1996-05-09 | 1996-07-10 | Royal Free Hosp School Med | Anticoagulant peptides |
| GB9609794D0 (en) * | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
| BR9713182A (pt) * | 1996-08-28 | 1999-11-03 | Procter & Gamble | Amidas de ácido fosfìnico como inibidores de metalo protease de matriz |
| KR100339296B1 (ko) * | 1996-08-28 | 2002-06-03 | 데이비드 엠 모이어 | 헤테로고리성 메탈로프로테아제 억제제 |
| ATE226573T1 (de) | 1996-08-28 | 2002-11-15 | Procter & Gamble | Heterozyklische metalloproteaseinhibitoren |
| RU2203274C2 (ru) * | 1996-08-28 | 2003-04-27 | Дзе Проктер Энд Гэмбл Компани | Спироциклические ингибиторы металлопротеаз |
| DE69716934T2 (de) * | 1996-08-28 | 2003-07-31 | The Procter & Gamble Company, Cincinnati | 1,3-diheterozyklische metalloprotease inhibitoren |
| IL128337A0 (en) | 1996-09-10 | 2000-01-31 | British Biotech Pharm | Cytostatic hydroxamic acid derivatives |
| US6462023B1 (en) | 1996-09-10 | 2002-10-08 | British Biotech Pharmaceuticals, Ltd. | Cytostatic agents |
| GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
| US5985911A (en) * | 1997-01-07 | 1999-11-16 | Abbott Laboratories | C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion |
| AU6843498A (en) * | 1997-03-28 | 1998-10-22 | Zeneca Limited | Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives |
| US6251913B1 (en) | 1997-03-28 | 2001-06-26 | Zeneca Limited | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
| US5883131A (en) * | 1997-07-09 | 1999-03-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| CA2298617A1 (fr) | 1997-07-31 | 1999-02-11 | Yetunde Olabisi Taiwo | Inhibiteurs de metalloprotease acycliques |
| US6576664B1 (en) * | 1997-08-18 | 2003-06-10 | Bristol-Myers Squibb Pharma Company | Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis |
| EP0897908A1 (fr) * | 1997-08-19 | 1999-02-24 | Roche Diagnostics GmbH | Acides 3-aryl-succinamido-hydroxamiques, procédé pour leur préparation et médicaments les contenant |
| ZA988967B (en) * | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| PT1021413E (pt) * | 1997-10-06 | 2003-10-31 | Wyeth Corp | A preparacao e utilizacao de acidos orto-sulfonamido heterociclicos biciclicos hidroxamicos como inibidores de metaloproteinases de matriz e de tace |
| EP1024134A4 (fr) * | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | Derives d'acide aminobutanoique |
| JP4948702B2 (ja) † | 1997-11-14 | 2012-06-06 | ザ プロクター アンド ギャンブル カンパニー | 孔あきトップシート上にスキンケア組成物を有する使い捨て吸収性製品 |
| BR9813719A (pt) | 1998-01-09 | 2000-10-17 | Pfizer | Agentes terapêuticos |
| WO1999041246A1 (fr) | 1998-02-11 | 1999-08-19 | Du Pont Pharmaceuticals Company | Nouveaux sulfamides cycliques utilises comme inhibiteurs des metalloproteases |
| GB2349149A (en) * | 1998-03-12 | 2000-10-25 | British Biotech Pharm | Cytostatic agents |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| US6447693B1 (en) | 1998-10-21 | 2002-09-10 | W. R. Grace & Co.-Conn. | Slurries of abrasive inorganic oxide particles and method for polishing copper containing surfaces |
| AU1219600A (en) | 1998-10-21 | 2000-05-08 | W.R. Grace & Co.-Conn. | Slurries of abrasive inorganic oxide particles and method for adjusting the abrasiveness of the particles |
| US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
| BR0008716A (pt) | 1999-03-03 | 2002-09-24 | Procter & Gamble | Inibidores de metaloprotease contendo alquenil ou alquinil |
| EP1165546A2 (fr) | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Nouveaux inhibiteurs de lactame de metalloproteases matricielles, de tnf-alpha, et de l'aggrecanase |
| EP1165500A1 (fr) | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Nouveaux derives d'amides faisant office d'inhibiteurs de metalloproteases matricielles, de tnf-alpha, et de l'aggrecanase |
| US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
| JP2001055327A (ja) * | 1999-06-11 | 2001-02-27 | Fuji Chemical Industries Ltd | 新規なヒドロキサム酸誘導体を含む医薬 |
| US6696456B1 (en) | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
| GB9929527D0 (en) * | 1999-12-14 | 2000-02-09 | Smithkline Beecham Plc | Novel compounds |
| US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| RU2189206C2 (ru) * | 2000-02-04 | 2002-09-20 | Ченцова Екатерина Валериановна | Способ лечения дефектов роговицы |
| US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
| NZ520657A (en) | 2000-03-21 | 2004-11-26 | Procter & Gamble | Heterocyclic side chain containing, N-substituted metalloprotease inhibitors |
| WO2001070693A2 (fr) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Inhibiteurs de metalloproteases d'acide difluorobutyrique |
| US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| EP1406893B1 (fr) | 2001-06-15 | 2007-04-18 | Vicuron Pharmaceuticals, Inc. | COMPOSeS BICYCLIQUES DE PYRROLIDINE |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| EP2316468A1 (fr) | 2002-02-22 | 2011-05-04 | Shire LLC | Système de distribution et méthodes de protection et d'administration de dextroamphetamine |
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| BRPI0407587A (pt) * | 2003-02-18 | 2006-02-14 | Pfizer | inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam |
| US7846963B2 (en) | 2003-05-17 | 2010-12-07 | Korea Research Institute Of Bioscience And Biotechnology | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
| EA009646B1 (ru) | 2003-05-30 | 2008-02-28 | Рэнбакси Лабораториз Лтд. | Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa |
| EP2287326A1 (fr) | 2003-08-08 | 2011-02-23 | Arriva Pharmaceuticals, Inc. | Procédés de production de protéines dans la levure |
| SI1663194T1 (sl) * | 2003-08-26 | 2010-08-31 | Merck Hdac Res Llc | Uporaba SAHA za zdravljenje mezotelioma |
| EP1737499A4 (fr) | 2004-03-09 | 2009-07-22 | Arriva Pharmaceuticals Inc | Traitement de la bronchopneumopathie chronique obstructive par inhalation a faible dose d'inhibiteur de protease |
| US8008302B2 (en) | 2004-07-26 | 2011-08-30 | Merck Serono Sa | N-hydroxyamide derivatives and use thereof |
| DE102005021806A1 (de) * | 2005-05-04 | 2006-11-16 | Lancaster Group Gmbh | Verwendung von radikalfangenden Substanzen zur Behandlung von Zuständen mit erhöhter Hauttemperatur, insbesondere zur antipyretischen Behandlung |
| CN101282962A (zh) | 2005-08-12 | 2008-10-08 | 先灵公司 | 用于治疗炎性疾病的化合物 |
| JP2009514851A (ja) | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | (3r,5r)−7−[2−(4−フルオロフェニル)−5−イソプロピル−3−フェニル−4−[(4−ヒドロキシメチルフェニルアミノ)カルボニル]−ピロール−1−イル]−3,5−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法 |
| DE102007027772A1 (de) * | 2007-06-16 | 2008-12-24 | Ab Skf | Anodnung zur Lagerung eines Maschinenteils |
| DE102007062199A1 (de) * | 2007-12-21 | 2009-06-25 | Evonik Degussa Gmbh | 2-Methylthioethyl-substituierte Heterocyclen als Futtermitteladditive |
| IT1401253B1 (it) | 2010-04-23 | 2013-07-18 | Uni Degli Studi Carlo Bo Urbino | Uso del sulodexide per la riduzione delle metalloproteinasi di matrice. |
| FR3010076B1 (fr) * | 2013-09-02 | 2016-12-23 | Centre Nat De La Rech Scient - Cnrs - | Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques |
| WO2015107139A1 (fr) * | 2014-01-17 | 2015-07-23 | Proyecto De Biomedicina Cima, S.L. | Composés destinés à être utilisés en tant qu'agents anti-fibrinolytiques |
| CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
| IT202100023357A1 (it) | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptidi con attività anti-angiogenica |
| PL447396A1 (pl) | 2023-12-29 | 2025-06-30 | Pikralida Spółka Z Ograniczoną Odpowiedzialnością | Krystaliczne formy polimorficzne marimastatu, postać amorficzna marimastatu, sposoby ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowania |
| PL447395A1 (pl) | 2023-12-29 | 2025-06-30 | Pikralida Spółka Z Ograniczoną Odpowiedzialnością | Sposób wytwarzania marimastatu, marimastat wytworzony tym sposobem, zawierająca go kompozycja farmaceutyczna oraz ich zastosowania |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL122359C (fr) * | 1964-03-06 | |||
| IT1201443B (it) * | 1985-07-31 | 1989-02-02 | Zambon Spa | Intermedi per la sintesi di acidi carbossilici |
| US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
| IT1198237B (it) * | 1986-12-23 | 1988-12-21 | Zambon Spa | Intermedi per la sintesi di composti organici |
| FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
| GB8827308D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| GB8919251D0 (en) * | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
| US5183900A (en) * | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
| ES2069833T3 (es) * | 1990-12-03 | 1995-05-16 | Celltech Ltd | Derivados peptidilicos. |
| CA2058797A1 (fr) * | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Derives d'aminoacide |
| GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
| JPH05125029A (ja) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
| GB9307956D0 (en) * | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
-
1992
- 1992-07-23 GB GB929215665A patent/GB9215665D0/en active Pending
-
1993
- 1993-07-22 GB GB9500722A patent/GB2287023B/en not_active Expired - Fee Related
- 1993-07-22 GB GB9315222A patent/GB2268934B/en not_active Expired - Fee Related
- 1993-07-22 GB GB9315206A patent/GB2268933B/en not_active Expired - Fee Related
- 1993-07-23 AU AU47153/93A patent/AU661410B2/en not_active Ceased
- 1993-07-23 ZA ZA935351A patent/ZA935351B/xx unknown
- 1993-07-23 AT AT96115235T patent/ATE198331T1/de not_active IP Right Cessation
- 1993-07-23 DE DE9321495U patent/DE9321495U1/de not_active Expired - Lifetime
- 1993-07-23 US US08/374,601 patent/US5643964A/en not_active Expired - Fee Related
- 1993-07-23 ES ES96115235T patent/ES2153927T3/es not_active Expired - Lifetime
- 1993-07-23 NZ NZ254862A patent/NZ254862A/en not_active IP Right Cessation
- 1993-07-23 DK DK96115235T patent/DK0754688T3/da active
- 1993-07-23 PL PL93307171A patent/PL174279B1/pl not_active IP Right Cessation
- 1993-07-23 SK SK78-95A patent/SK281240B6/sk unknown
- 1993-07-23 PT PT96115235T patent/PT754688E/pt unknown
- 1993-07-23 AT AT93917900T patent/ATE162183T1/de active
- 1993-07-23 EP EP93917901A patent/EP0651739B1/fr not_active Expired - Lifetime
- 1993-07-23 DE DE69329804T patent/DE69329804T2/de not_active Expired - Fee Related
- 1993-07-23 AT AT93917901T patent/ATE151414T1/de not_active IP Right Cessation
- 1993-07-23 EP EP93917900A patent/EP0651738B1/fr not_active Expired - Lifetime
- 1993-07-23 WO PCT/GB1993/001556 patent/WO1994002446A1/fr not_active Ceased
- 1993-07-23 KR KR1019950700232A patent/KR100205710B1/ko not_active Expired - Fee Related
- 1993-07-23 AU AU47152/93A patent/AU4715293A/en not_active Abandoned
- 1993-07-23 WO PCT/GB1993/001557 patent/WO1994002447A1/fr not_active Ceased
- 1993-07-23 HU HU9500202A patent/HU220625B1/hu not_active IP Right Cessation
- 1993-07-23 JP JP6504307A patent/JP2768554B2/ja not_active Expired - Fee Related
- 1993-07-23 CA CA002140626A patent/CA2140626C/fr not_active Expired - Fee Related
- 1993-07-23 EP EP96115235A patent/EP0754688B1/fr not_active Expired - Lifetime
- 1993-07-23 RU RU95109920/04A patent/RU2126791C1/ru not_active IP Right Cessation
- 1993-07-23 DE DE4393452T patent/DE4393452T1/de not_active Ceased
- 1993-07-23 DE DE69316367T patent/DE69316367T2/de not_active Expired - Fee Related
- 1993-07-23 DK DK93917901.6T patent/DK0651739T3/da active
- 1993-07-23 DE DE69309686T patent/DE69309686T2/de not_active Expired - Fee Related
- 1993-07-23 US US08/374,602 patent/US5700838A/en not_active Expired - Fee Related
- 1993-07-23 CZ CZ95157A patent/CZ285896B6/cs not_active IP Right Cessation
- 1993-07-23 ZA ZA935352A patent/ZA935352B/xx unknown
- 1993-07-23 UA UA95018066A patent/UA29450C2/uk unknown
- 1993-07-23 JP JP6504306A patent/JPH07509459A/ja active Pending
-
1995
- 1995-01-20 FI FI950262A patent/FI114549B/fi not_active IP Right Cessation
- 1995-01-20 NO NO950226A patent/NO303221B1/no unknown
- 1995-06-12 HU HU95P/P00187P patent/HU211287A9/hu unknown
-
1996
- 1996-08-08 HK HK149396A patent/HK149396A/xx not_active IP Right Cessation
-
1997
- 1997-05-16 CY CY194497A patent/CY1944A/en unknown
- 1997-05-23 GR GR970401170T patent/GR3023522T3/el unknown
- 1997-10-23 US US08/956,338 patent/US5912360A/en not_active Expired - Lifetime
- 1997-12-22 JP JP9353810A patent/JP2971053B2/ja not_active Expired - Fee Related
-
2001
- 2001-03-05 GR GR20010400350T patent/GR3035510T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO303221B1 (no) | Hydroksaminsyrederivater | |
| CY1109863T1 (el) | Παραγωγα θειαζολης για χρηση ως αντιφλεγμονωδη | |
| NL300215I1 (nl) | Depsipeptide-derivaat, productie daarvan en toepassing daarvan. | |
| ES2046229T3 (es) | Composicion antiulcerosa. | |
| NO900732D0 (no) | Arylalkylaminforbindelser. | |
| DK0478173T3 (da) | 4,5-polymethylen-4-isothiazolin-3-onderivater og anvendelse heraf som biocider | |
| BR9103236A (pt) | Composto pesticida,processo para sua preparacao,composicao pesticida e processo para combater pragas | |
| ZA906446B (en) | Therapeutic agents for the treatment of peptic ulcer disease | |
| DE69016266D1 (de) | Aminoketonverbindungen. | |
| ES8303381A1 (es) | Procedimiento para la fabricacion de un compuesto de fenil- 1,3-perhidrotiacina-4-ona, 2-substituida | |
| FI900796A0 (fi) | Aralkylaminfoereningar. |